Latest News about MKGAF
Recent news which mentions MKGAF
From Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
February 16, 2025
From Benzinga
From Benzinga
From Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
From Benzinga
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
September 26, 2023
From Benzinga
From Benzinga
From Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
June 20, 2023
From Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
May 17, 2023
From Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
April 18, 2023
From Benzinga
From Benzinga
From Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
From Benzinga
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
January 03, 2023
From Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
December 23, 2022
From Benzinga
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
From Benzinga
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
September 21, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.